还原型谷胱甘肽对酒精性肝炎患者肝纤维化指标的影响

目的：观察酒精性肝炎患者使用还原型谷胱甘肽治疗后肝纤维化指标的改善情况及临床症状、体征、肝功能的变化。方法：将72例酒精性肝炎患者分成治疗组（37例）和对照组（35例），对照组给予甘利欣、门冬氨酸钾镁注射液、多种维生素等综合治疗，治疗组在综合治疗的基础上加用还原型谷胱甘肽（1．5g，一日一次），疗程均为8周。观察治疗前后两组的血清纤维化指标透明质酸（HA）、层粘连蛋白（LN）、Ⅲ型前胶原N端肽（PⅢ-P）、Ⅳ型胶原（C-Ⅳ）]及生化指标总胆红素（TBIL）、ALT、AST、γ-谷氨酰转肽酶（GGT）]的变化。结果：治疗组在症状、体征、肝功能、血清纤维化的改善方面明显优于对照组，治疗组血清肝纤维化指标与治疗前相比均有明显下降（P〈0．01），而对照组下降不明显，两组相比有统计学差异（P〈0．01）。结论：还原型谷胱甘肽对酒精性肝炎患者有明显的抗纤维化作用和保肝护肝作用。

Reduced glutathione hormone's impact on alcoholic hepatitis patient's index of hepatic fibrosis

AIM: To observe the changes of hepatic fibrosis index, clinical symptom, physical sign and hepatic function after the patients were treated treatment with reduced glutathione hormone. METHODS: The 72 patients were divided into two groups that one was the treatment group with 37 patients and the other was the control group with 35 patients. The control group was accepted the treatment with Ganlixin Injection, Magnesium Aminosuccinate Injection and Mulvi-tal, etc. The treatment group was accepted reduced glutathione hormone (1.5 g, once a day) in addition. The course of treatment lasted for 8 weeks. We observed the two groups' blood-serum fibrosis indexes (HA, LN, PIII-P, C-IV)and biochemistry indxes (TBIL, ALT, AST, GGT) before and after the treatment. RESULTS: The improvements of the treatment group were much better than the control group on the sides of clinical symptom, physical sign, hepatic function and blood-serum fibrosis. The treatment group's blood-serum fibrosis indexes were much lower after the treatment (P < 0.01), and there was no clear decline in the control group. There were obvious differences between the two groups(P < 0.01). CONCLUSION: holic hepatitis; hepatic fibrosis Reduced glutathione hormone has the significant effects of anti-fibrosis and liver protection.